Barbara Geering

Barbara Geering

Auto-generated profile, based on publicly available information

Barbara Geering

Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SGSimon Gutbier
Simon Gutbier
FWFlorian Wanke
Florian Wanke
NDNadine Dahm
Nadine Dahm
ARAnna Rümmelin
Anna Rümmelin
SZSilke Zimmermann
Silke Zimmermann
CPChristoph Patsch
Christoph Patsch
Tissue-resident macrophages are key players in inflammatory processes, and their activation and functionality are crucial in health and disease. Numerous diseases are associated with alterations in homeostasis or dysregulation of the innate immune system, including allergic reactions, autoimmune diseases, and cancer. Macrophages are a prime target for drug discovery due to their major regulatory role in health and disease. Currently, the main sources of macrophages used for therapeutic compound screening are primary cells isolated from blood or tissue or immortalized or neoplastic cell lines (e.g., THP-1). Here, we describe an improved method to employ induced pluripotent stem cells (iPSCs) for the high-yield, large-scale production of cells resembling tissue-resident macrophages. For this, iPSC-derived macrophage-like cells are thoroughly characterized to confirm their cell identity and thus their suitability for drug screening purposes. These iPSC-derived macrophages show strong cellular identity with primary macrophages and recapitulate key functional characteristics, including cytokine release, phagocytosis, and chemotaxis. Furthermore, we demonstrate that genetic modifications can be readily introduced at the macrophage-like progenitor stage in order to interrogate drug target-relevant pathways. In summary, this novel method overcomes previous shortcomings with primary and leukemic cells and facilitates large-scale production of genetically modified iPSC-derived macrophages for drug screening applications.

25 May 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
FWFlorian Wanke
Florian Wanke
SGSimon Gutbier
Simon Gutbier
ARAnna Rümmelin
Anna Rümmelin
MSMalte Steinberg
Malte Steinberg
LHLindsey D. Hughes
Lindsey D. Hughes
BGBarbara Geering
Barbara Geering
Removal of apoptotic cells by phagocytes (also called efferocytosis) is a crucial process for tissue homeostasis. Professional phagocytes express a plethora of surface receptors enabling them to sense and engulf apoptotic cells, thus avoiding persistence of dead cells and cellular debris and their consequent effects. Dysregulation of efferocytosis is thought to lead to secondary necrosis and associated inflammation and immune activation. Efferocytosis in primarily murine macrophages and dendritic cells has been shown to require TAM RTKs, with MERTK and AXL being critical for clearance of apoptotic cells. The functional role of human orthologs, especially the exact contribution of each individual receptor is less well studied. Here we show that human macrophages differentiated in vitro from iPSC-derived precursor cells express both AXL and MERTK and engulf apoptotic cells. TAM RTK agonism by the natural ligand growth-arrest specific 6 (GAS6) significantly enhanced such efferocytosis. Using a newly-developed mouse model of kinase-dead MERTK, we demonstrate that MERTK kinase activity is essential for efferocytosis in peritoneal macrophages in vivo. Moreover, human iPSC-derived macrophages treated in vitro with blocking antibodies or small molecule inhibitors recapitulated this observation. Hence, our results highlight a conserved MERTK function between mice and humans, and the critical role of its kinase activity in homeostatic efferocytosis.

1 August 2015 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
BGBarbara Geering
Barbara Geering

24 October 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
HCHélène Chassin
Hélène Chassin
BGBarbara Geering
Barbara Geering
LSLina Schukur
Lina Schukur
DADavid Ausländer
David Ausländer
BLBrian Lang
Brian Lang
MFMartin Fussenegger
Martin Fussenegger
While constantly rising, the prevalence of allergies is globally one of the highest among chronic diseases. Current treatments of allergic diseases include the application of anti-histamines, immunotherapy, steroids, and anti-immunoglobulin E (IgE) antibodies. Here we report mammalian cells engineered with a synthetic signaling cascade able to monitor extracellular pathophysiological levels of interleukin 4 and interleukin 13, two main cytokines orchestrating allergic inflammation. Upon activation of transgenic cells by these cytokines, designed ankyrin repeat protein (DARPin) E2_79, a non-immunogenic protein binding human IgE, is secreted in a precisely controlled and reversible manner. Using human whole blood cell culturing, we demonstrate that the mammalian dual T helper 2 cytokine sensor produces sufficient levels of DARPin E2_79 to dampen histamine release in allergic subjects exposed to allergens. Hence, therapeutic gene networks monitoring disease-associated cytokines coupled with in situ production, secretion and systemic delivery of immunomodulatory biologics may foster advances in the treatment of allergies.

14 October 2016 in Cell Death & Differentiation
Verified
Journal Article
Closed access
CSChristina Stoeckle
Christina Stoeckle
BGBarbara Geering
Barbara Geering
SYShida Yousefi
Shida Yousefi
SRSaša Rožman
Saša Rožman
NANicola Andina
Nicola Andina
Hans-Uwe SimonHans-Uwe Simon
Hans-Uwe Simon

8 September 2015 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
LSLina Schukur
Lina Schukur
BGBarbara Geering
Barbara Geering
MFMartin Fussenegger
Martin Fussenegger